Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) stock closed at $222.90 on 6/24/24 after a major increase of 34.5%. Moreover, trading volume in this advance was exceptionally high at 1189% of normal. Relative to the market the stock has been weak over the last nine months but has risen 39.3% during the last week.
Current PriceTarget Research Rating
With future capital returns forecasted to be below the cost of capital, ALNY is expected to be a major Value Eraser.
Alnylam Pharmaceuticals is currently unrated.
Rating Review
The stock is currently unrated.
Be the first to comment